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ABSTRACT
In locally advanced rectal cancer a preoperative predictive biomarker is necessary 
to adjust treatment specifically for those patients expected to suffer relapse. We 
applied whole genome methylation CpG island array analyses to an initial set of 
patients (n=11) to identify differentially methylated regions (DMRs) that separate 
a good from a bad prognosis group. Using a quantitative high-resolution approach, 
candidate DMRs were first validated in a set of 61 patients (test set) and then 
confirmed DMRs were further validated in additional independent patient cohorts 
(n=71, n=42). We identified twenty highly discriminative DMRs and validated them 
in the test set using the MassARRAY technique. Ten DMRs could be confirmed which 
allowed separation into prognosis groups (p=0.0207, HR=4.09). The classifier was 
validated in two additional cohorts (n=71, p=0.0345, HR=3.57 and n=42, p=0.0113, 
HR=3.78). Interestingly, six of the ten DMRs represented regions close to the 
transcriptional start sites of genes which are also marked by the Polycomb Repressor 
Complex component EZH2. In conclusion we present a classifier comprising 10 DMRs 
which predicts patient prognosis with a high degree of accuracy. These data may now 
help to discriminate between patients that may respond better to standard treatments 
from those that may require alternative modalities.
INTRODUCTION
Preoperative radiotherapy (RT) is standard in 
the treatment of locally advanced rectal cancer [1, 2]. 
Combining preoperative RT with 5-Fluorouracil (5-FU) 
increased local control [3] and resulted in a significantly 
decreased local recurrence rate compared to postoperative 
radiochemotherapy (CRT) [4]. However, even after ten 
years, successful reduction of local relapse has had no 
impact on disease-free (DFS) or overall survival [5]. 
Accordingly, the occurrence of distant metastases is a 
limiting factor, demonstrating the need of alternative 
treatments.
A significant proportion of patients receiving 
standard preoperative CRT responds to the therapy and 
does not experience distant metastases. Therefore, a 
more aggressive standard therapy for all patients would 
result in overtreatment of patients with an otherwise 
good prognosis whereby these patients would endure 
unnecessary toxicity. An a priori assessment of patients 
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prior to therapy would therefore enable a risk-adapted 
approach. A similar strategy based on radiological 
assessment of high-risk patient groups was recently 
followed in the EXPERT-C trial [6].
Multifold molecular analyses have been applied to 
take advantage of the tumor biology in risk stratification 
or response prediction. However, the vast majority of 
analyses focused on single markers and failed to be 
validated in larger patient groups [7]. Interestingly, 
analyses of DNA methylation are rare, even though the 
regulation of transcriptional activity by methylation of 
cytosine residues is well known and constitutes a rather 
stable DNA modification [8, 9]. Moreover, changes 
in DNA methylation are also frequently associated 
with or indicative of other epigenetic changes, such as 
changes in histone modifications [10]. Furthermore, 
hypermethylation of specific regions is a frequent 
alteration observed in many different cancer types 
[11, 12].
Considering the complexity of DNA methylation 
changes in cancer, and in order to avoid missing the most 
promising regions, we performed an unbiased methylome 
analysis using a CpG island microarray. Secondly, using 
a matrix-assisted laser desorption/ionization (MALDI) 
time-of-flight (TOF) mass spectrometry-based (MS) 
technique (MassARRAY®), a subset of candidate 
prognosis-associated differentially methylated regions 
(DMRs) was assessed in a test set of patients (n=61). 
Selected DMRs were subsequently validated in a set of 
patients treated with preoperative CRT (n=71) as well as 
in a more heterogeneous set of patients treated with RT 
and CRT (n=42). The increased prognostic power of the 
CpG methylation signature compared to the previously 
analyzed CIMP was revealed.
RESULTS
Identification of DMRs
Genome-wide DNA methylation analysis was 
performed on 11 corresponding tumor and mucosa 
samples (screening set) using CpG island arrays. Data 
were analyzed for differentially methylated probes 
comparing good versus bad prognosis. Applying the 
above-mentioned criteria to DMRs, we identified 
a subset of 20 DMRs located within or close to 17 
different genes (Supplementary Table 2). The majority 
of DMRs were distributed over chromosomes 1 (n=4), 
19 (n=3), and 20q13 (n=5). This distribution could 
not be attributed to the frequency of array probes on 
the diverse chromosomes (p=7.6*10-11, Supplementary 
Figure 1).
Target validation
To test the validity of the 20 identified DMRs, 
a group of 61 patients (test-set) was analyzed using 
MassARRAY®. Ten DMRs correlated significantly 
with DFS (p< 0.05). These DMRs were associated with 
genes ADAP1, BARHL2, CABLES2, DOT1L, ERAS, 
ESRRG, RNF220, ST6GALNAC5, TAF4, and SLC20A2. 
Unsupervised hierarchical clustering displayed a 
Figure 1: Study overview. Study design comprising four different independent cohorts (MCIp - Methyl-CpG immunoprecipitation,  DMR – 
differentially methylated region, MassARRAY® (technique by Sequenome) - matrix-assisted laser desorption/ionization (MALDI) time-of-flight 
(TOF) mass spectrometry (MS), CRT – chemoradiotherapy, RT – radiotherapy, GER – German cohort, FRA – French cohort)
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clear separation of patients into a high (n=31) or low 
methylation group (n=29) (Figure 2A). Log rank testing 
revealed a significantly better prognosis (p=0.0207, 
HR=4.09, 95%-CI=[1.12,14.87]) for the high methylation 
group (Figure 2B). An analysis of deviance comparing the 
full Cox model to that without methylation demonstrates 
a significantly better fit if methylation is part of the model 
(p=0.04). Analyzing for cancer-specific survival (CSS), 
only n=27 events occurred. Eleven DMRs significantly 
correlated with CSS, resulting in two patient groups. 
However, log rank testing failed to display any significant 
difference
Figure 2: DFS of different patient cohorts. A) Methylation sites measured in the test-Set were filtered for their correlation with 
DFS using a Cox regression. Based on the filtered CpGs a clustering was performed which is shown on the heatmap. The dendrogram on 
the columns illustrates a hyper- and a hyopmethylated group. B) The Kaplan-Meier estimates of these groups were compared using a log-
rank test indicating a significant difference between hyper- and hypomethylated tumors indicating a good and a bad prognosis groups. The 
patients from the validation set GER C) and FRA D) were assigned to one of the clusters based on their methylation pattern by means of the 
nearest centroid distance. The Kaplan-Meier curves of the resulting patient groups were again compared using a log-rank test. Correlation 
to DFS again revealed significant differences. (DFS – Diseas Free Survival)
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Independent validation
Initial independent validation of the identified panel 
of 10 DMRs was performed on a set of 71 patients. Based 
on the methylation pattern of their tumor, patients were 
assigned to one of two clusters (good or bad prognosis). 
Comparing the survival curves of the resulting patient 
groups by means of a log-rank test, a significant difference 
(p=0.0345, HR=3.57, 95%-CI=[1.01, 12.55]) between 
both groups (Figure 2C) was again observed. Although 
comparison between the full model and that without 
methylation reveals a better fit for the full model, it was 
slightly over the 5% significance level (p=0.07).
A second validation of the 10 DMRs was applied 
to a more heterogeneous group of 42 patients [13]. After 
patients were assigned to a good or bad prognosis group a 
clear difference was observed (p=0.0113, HR=3.78, 95%-
CI=[1.26,11.37]; Fig. 2D). Comparison between the full 
model and the model without methylation also results in 
a significantly better fit for the model with methylation 
(p=0.04).
Comparison of CIMP and clinical data
To compare the newly identified gene set to our 
previous data on CIMP, we also applied the MassARRAY® 
technology to the specific CIMP panel but did not achieve 
statistical significance between the identified patient 
groups. To assess any further predictive value of these 
genes, both models were combined. However, the CIMP 
model did not add any additional predictive information 
compared to the whole genome model as illustrated in 
Supplementary Figure 2.
In addition to molecular analyses, preoperatively 
assessed clinical data are considered to have an influence 
on outcome. Accordingly, pretherapeutic tumor category 
or lymph node status were analyzed for any correlation to 
DFS using a univariate Cox regression model. However, 
both parameters failed to demonstrate any significant 
correlation (p=0.97 and p=0.08). Consequently, neither the 
CIMP genes nor the clinical data were used to complement 
the methylation profile identified from the CpG island 
methylome approach.
Correlation of DMRs with Polycomb Repressor 
Complex occupancy
Like DNA methylation, a number of repressive 
post-translational histone modifications have been 
shown to be associated with tumorigenesis. Notably, 
a recent report suggested that a sequential epigenetic 
silencing process occurs during colorectal cancer 
tumor progression. In this model inactive genes are 
initially “poised” by being epigenetically marked by 
trimethylation of lysine 27 on histone H3 (H3K27me3) 
via the Polycomb Repressor Complex-2 component 
EZH2 [14]. The authors propose a model in which 
these genes become inactivated by subsequent DNA 
methylation during tumor progression. Therefore we 
utilized published chromatin immunoprecipitation 
sequencing (ChIP-seq) data in various cell types 
from the ENCODE consortium. Strikingly, six of 
the ten DMRs (near the ADRA1A, BARHL2, ERAS, 
ESRRG, RNF220 and ST6GALNAC5 genes) showed an 
enrichment of EZH2 (Figure 3).
DISCUSSION
The differing response of patients with rectal cancer 
to preoperative radiochemotherapy as well as variable 
prognosis requires pre-therapeutic patient stratification. 
However, valid markers are still lacking. Consistent 
with our findings, analyzing pre-therapeutic clinical 
parameters such as localization or staging has failed 
to prove significant [15]. According to the EXPERT-C 
trial, the radiological assessment of the circumferential 
margin (CRM) has emerged as a possible parameter in 
the assessment of patients which has a high specificity 
[16]. However, radiological assessment of the CRM 
only identifies the localization of the tumor in relation to 
the mesorectal fascia and/or intersphincteric plane, but 
cannot assess the relation of the tumor to the final surgical 
boundary [17, 18]. Moreover, the definition disregards 
aggressive tumors that are small in size.
We therefore applied DNA methylation analyses to 
identify relevant methylation targets for the prediction of 
outcome in patients with advanced rectal cancer treated 
with CRT preoperatively. In an initial genome-wide 
screen on eleven patients, the 20 most representative 
DMRs were identified. These DMRs were preferentially 
and non-randomly distributed over chromosomes 1, 
19, and 20q13.33, an area known for genetic variants 
associated with colorectal cancer [19, 20]. Linkage 
of DMRs suggests a common process responsible for 
aberrant methylation of the affected genomic regions 
which may involve the Polycomb Repressor Complex 
component EZH2. In a first set of patients, all 20 DMRs 
were tested for their ability to separate patients into a 
good or bad prognosis group. Within this test set, ten 
DMRs were significantly associated with DFS and 
clearly separated patients into a good or bad prognosis 
group. To further assess the predictive validity of these 
DMRs, they were validated in a set of 71 additional 
patients. The significant separation into a good or a 
bad prognosis group as identified by the Cox model 
underlined the predictive power of the retrieved 
methylation signature. In a second validation the 
signature was applied to a heterogeneous patient set that 
corresponds to a routine single-center trial. Patients were 
treated with radiotherapy only or in combination with 
5-FU within previous clinical trials in France [3, 21].
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Figure 3: Enrichment of EZH2 at rectal cancer DMRs. ChIP-seq data from H1 human embryonic stem cells, human umbilical 
vein endothelial cells, and normal human astrocytes obtained by the ENCODE consortium were analyzed for the occupancy of the 
Polycomb Repressor Complex-2 component EZH2 at the investigated rectal cancer-associated DMRs. As shown, significant signals of 
EZH2 occupancy were observed at the RNF220, ST6GALNAC5, BARHL2, ESRRG, ADRA1A and ERAS genes. The location of the DMRs 
is indicated by the black boxes located below the gene coordinates.
It is important to acknowledge the treatment 
differences between the German and French cohorts 
with respect to preoperative therapy. The French cohort 
underwent primarily radiotherapy only with a small 
minority of patients receiving 5-FU in combination. 
Furthermore, the patients within the French cohort were 
not treated in an adjuvant setting. However, these patients 
were again separated into a good or bad prognosis group 
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with respect to DFS. Accordingly, one may hypothesize 
that the signature is not restricted to a specific therapy, 
but rather allows a more generalized differentiation into 
more or less aggressive tumors. Therefore, it appears 
reasonable that each type of preoperative therapy may 
require a distinct methylation panel to predict the outcome 
precisely. Nevertheless, this needs to be analyzed on a 
larger patient cohort.
Interestingly, many of the identified DMRs within 
the signature are localized close to genes already 
associated with cancer, such as MEF2C and TAF4 [22]. 
BARHL2, a homebox gene, was found to be methylated 
in lung cancer [23] or astrocytomas [24]. DOT1L 
encodes a histone methyltransferase acting at lysine-79 
of histone H3 [19] which was recently been shown to 
be an activator in colorectal cancer [25] and functions 
in DNA repair in yeast [26]. ERAS is epigenetically 
regulated and was shown to act as an oncogene by 
producing a constitutively active Ras protein [27]. 
Furthermore, its expression was revealed to mediate 
resistance to chemotherapy [28, 29]. CABLES2 is 
involved in both p53-mediated and p53-independent 
apoptosis [30]. ST6GALNAC5, an enzyme which 
controls cell-cell or cell-extracellular matrix interactions 
[31] was also found in the signature. Other genes play 
a role in epigenetic regulation. ESRRG belongs to a 
receptor family functioning as a transcriptional activator 
of DNA cytosine-5-methyltransferases 1 (DNMT1) [20]. 
Ring finger protein 220 (RNF220) was shown to be a 
ubiquitin ligase targeting Sin3B thereby regulating the 
activity of the Sin3/HDAC corepressor complex [32]. 
Notably, many of these genes (ADRA1A, BARHL2, 
ERAS, ESRRG, RNF220 and ST6GALNAC5) are also 
targets of the Polycomb Repressor Complex-2, further 
supporting an important role of epigenetic crosstalk in 
controlling rectal cancer therapeutic responsiveness.
While DNA methylation has already been 
analyzed in order to identify prognostic or predictive 
markers in rectal cancer in the past, these studies 
differed in their end-point and generally only 
analyzed smaller marker panels. Molinari et al. 
assessed the methylation status of 24 different tumor 
suppressor genes [33]. Except for the TIMP3 gene no 
correlation to tumor regression grading and therefore 
the response to preoperative radiochemotherapy 
could be found. As a relevant endpoint for 
prognosis De Maat et al. focused on methylated- 
in-tumor (MINT) to assess the local recurrence rate [34]. 
Different methylation levels correlated to patient groups 
that were correlated to local recurrence. A large study by 
Kohonen-Corish et al. on 381 patients assessed BRAF 
and KRAS mutations, CIMP and microsatellite status as 
well as CDKN2A methylation [35]. KRAS mutation as 
well as CDKN2A methylation level was associated with 
prognosis and if found within the same tumor turned 
the prognosis was even worse. However, only 5% of the 
patients were treated preoperatively. Accordingly, these 
data cannot be compared. A recent study by Benard et 
al. analyzed 214 early rectal cancer patients that were 
also not treated by preoperative radiochemotherapy [36]. 
These showed a correlation between poor prognosis and 
hypomethylation of LINE-1 elements. Interestingly, 
Alu methylation status did not correlate with prognosis 
indicating a more specific role of LINE-1 with respect 
to prognosis compared with just the global methylation.
In colorectal cancer the CpG island methylator 
phenotype (CIMP) represents a distinct molecular 
subtype [37]. However, in the past different definitions 
of CIMP as well as technical variations have led to 
conflicting results as reviewed by Hughes et al. [38]. 
Moreover, the advantage of quantitative approaches over 
dichotomized values have been proposed by Claus et al. 
[39]. We therefore used the MassARRAY® technique 
to assess CIMP phenotype in rectal cancer patients. A 
small number of the analyzed CpGs from the RUNX3, 
IGF2, SOCS1, and MINT1 genes showed a significant 
correlation between prognosis and methylation 
status, however, the number of patients considered as 
hypermethylated was small and the distinction between 
the two groups failed to show a clear correlation to 
disease free survival (Supplementary Figure 2). The 
small number of CIMP positive patients in rectal cancer 
has recently been reevaluated by Bae et al. [40] and a 
correlation between prognosis and CIMP status in the 
rectum was confirmed. Accordingly, CIMP should be 
considered as a small but relevant molecular marker in 
rectal cancer. With respect to previous data and the lack 
of concordance it should be acknowledged that the use 
of quantitative analyses led to a decreased number of 
patients in the CIMP positive group [39], resulting in 
an unbalanced analysis. Furthermore, the incomplete 
overlap between the DMRs assessed by MSP and 
MassArray likely contribute to these findings.
Aiming for individualized rectal cancer treatment, 
new trial designs based on the prediction of good or 
bad prognosis are needed. Accordingly, patients in the 
good prognosis group would receive standard, low-
toxicity treatment. Patients assigned to a poor prognosis 
group should be subjected to intensified protocols at 
the cost of increased therapy-related toxicity. These 
regimens based on induction chemotherapy including 
antibody therapy before CRT [41, 42] have already been 
evaluated in the image-guided EXPERT-C trial [6] and 
displayed promising results with respect to prognosis. 
Certainly, the robustness of these data must be further 
analyzed. However, the methylation signature was 
reproducible despite the presence of a certain degree of 
patient heterogeneity. Patient cohorts differed by having 
a multicenter accrual and two validation sets, one from 
Germany and one from France. Nevertheless, prior to 
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using these data for therapeutic decision making, they 
should be independently validated. As the different data 
sets have been retrieved by “all-in-one-batch-analyses” 
the assessment of methylation status “biopsy by biopsy” 
is another prerequisite. Furthermore, application of a more 
accessible technique and the reproducibility in FFPE 
samples are also relevant steps to assure the robustness.
In summary, we adopted a global methylome 
approach to identify potential targets that can predict 
outcome in advanced rectal cancer. Ten DMRs were 
identified and validated in two independent patient sets. 
This methylation panel represents the first validated global 
approach to pretherapeutic prediction in rectal cancer. If 
validated in a prospective trial, this signature could be 
applied to identify patients at high risk of developing 
distant metastases. Thus, stratification of preoperatively-
treated rectal cancer patients using an individualized 
therapy approach based on molecular markers such as 
DMRs may indeed be achievable.
MATERIAL AND METHODS
Patients and treatment
Overall, 185 patients with preoperatively treated 
rectal cancer (0–12 cm from the anocutaneous verge) 
were included in the study (Table 1). One hundred and 
fifty-two patients were treated within or according to the 
CAO/ARO/AIO-94 or CAO/ARO/AIO-04 trial [4, 43]. 
Treatment was based on preoperative CRT comprising 
a total radiation dose of 50.4 Gy (single dose of 1.8 
Gy) accompanied by either 5-FU or a combination of 
an intravenous infusion of oxaliplatin and 5-FU. Total 
mesorectal excision was performed 4 to 6 weeks after 
preoperative CRT. Patients were followed up according 
to the trial standards and provided written informed 
consent according to the guidelines set by the ethics 
committee of the University Medical Center Goettingen. 
Tumor and corresponding mucosa biopsies were taken 
during staging procedures prior to any therapy. A small 
set (n=11) was stored in liquid nitrogen while the vast 
majority was transferred to RNAlater (Ambion, Austin, 
TX) immediately after removal. Histopathologic work-up 
confirmed tumor tissue; a tumor-cell content of at least 
50% was required for inclusion into the study. Forty-two 
samples from the “Lyon molecular signature” panel [13] 
were retrieved from patients who were treated in two 
randomized trials [3, 21]. These patients were treated 
differently and served as a validation panel. The dose 
of external beam radiation was 39 Gy (13×3 Gy) in the 
Lyon R 96 02 trial and 45 Gy in 25 fractions (1.8 Gy) 
over five weeks when included in FFCD 9203 trials. In 
the FFCD 9203 trial, patients were treated with concurrent 
5-FU during the first and fifth week of external radiation. 
Biopsies taken prior to therapy were stored in liquid 
nitrogen without pathologic control [13].
The study design comprised a three-step 
procedure: first, a genome-wide CpG island screen for 
targets; second, testing of the most favorable targets; 
and third, a final validation (Figure 1). The screening 
and subsequent testing of identified regions was only 
performed on pretherapeutic biopsies of n=11 and n=61 
patients treated in Goettingen. To validate these findings 
we utilized a German multicenter patient set (n=71) 
that was treated in an equivalent manner to the patients 
from the screening and test sets. Transferability of the 
identified signature was further validated with the n=42 
patients from the “Lyon molecular signature” panel [13]. 
Due to the absence of an adequate follow-up but the 
need for fresh frozen biopsies to perform the genome-
wide CpG scan, targets were selected based on tumor 
regression grading (TRG) and post-therapeutic lymph 
node status (ypN) after CRT. Both parameters are known 
to be well-established surrogate parameters for outcome 
in rectal cancer [15, 44–48]. The study was conducted 
in accordance with the Helsinki Declaration and was 
approved by the ethics committee of the University 
Medical Center Goettingen.
DNA Isolation
For samples stored in liquid nitrogen, DNA isolation 
was performed using QIAamp DNA Mini Kit (Qiagen) 
according to the manufacturer’s recommendations. 
In brief, frozen biopsies were disrupted using the 
TissueRuptor (Qiagen). Lysis was complemented with 
Proteinase K digest and DNA integrity was controlled by 
gel electrophoresis.
DNA from RNAlater samples was isolated using 
TRIZOL (Invitrogen, Carlsbad, CA) following standard 
procedures as previously described [49].
MCIp enrichment and CpG island 
microarray analysis
MCIp enrichment of highly methylated DNA 
and CpG island microarray analysis was performed as 
described previously with minor modifications [50, 51]. 
Briefly, 2.5 µg DNA was sonicated with the Bioruptor 
NGS (Diagenode, Liege, Belgium) to fragments of 100 
to 600 basepairs (bp). Fragmented DNA was MCIp-
enriched using an SX-8G IP-Star robot (Diagenode) and 
60 µg MBD2-Fc protein coupled to protein A magnetic 
beads (Diagenode). Proper DNA enrichment was 
monitored by quantitative real-time PCR targeting the 
imprinted gene SNRPN. The non-methylated allele 
elutes at low-salt, while the methylated allele elutes 
at high-salt concentration. Highly methylated tumor 
and healthy control DNA (matched normal mucosa 
from nearby the tumor) were labeled with Alexa Fluor 
5 and 3, respectively, and cohybridized to a 244 K 
human CpG island microarray (Agilent, Germany, 
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Table 1:  Clinical data of enrolled patients: Comparison of basic study parameters between test and 
validation sets. Significant differences in the pre- and posttherapeutic therapy was due to the French cohort 
(GER – German cohort, FRA –French cohort, uT and uN – T-stage and lymph node status assessed by 
ultrasound, cM – clinically assessed distant metastases, 5-FU – 5-Fluorouracil, Ox – Oxaliplatin, RT – 
Radiotherapy, ypT and ypN – histopathologically assessed T-stage and lymph node status after preoperative 
therapy, yM – status of distant metastases after preoperative therapy, DFS – disease-free survival, CSS- 
cancer-specific survival)





n 11 61 71 42
Age [years] 1.0
 mean ± sd 66 ± 7.7 64 ± 11 63 ± 10 67 ± 10
 median (min; max) 65 (50; 77) 64 (36; 81) 63 (38; 80) 69 (42; 80)
Gender 1.0
 female 5 (45.5%) 18 (29.5%) 19 (26.8%) 18 (42.9%)
 male 6 (54.5%) 43 (70.5%) 52 (73.2%) 24 (57.1%)
uT 1.0
 2 0 (0.0%) 1 (1.6%) 3 (4.3%) 5 (11.9%)
 3 10 (90.9%) 57 (93.4%) 63 (90.0%) 36 (85.7%)
 4 1 (9.1%) 3 (4.9%) 4 (5.7%) 1 (2.4%)
 NA 0 0 1 0
uN 1.0
 0 1 (9.1%) 17 (27.9%) 24 (35.8%) 13 (31.0%)
 1 10 (90.9%) 44 (72.1%) 43 (64.2%) 29 (69.0%)
 NA 0 0 4 0
cM 0.3
 0 11 (100.0%) 60 (98.4%) 63 (88.7%) 42 (100.0%)
 1 0 (0.0%) 1 (1.6%) 8 (11.3%) 0 (0.0%)
Preoperative Therapy 0.01
 5-FU + RT 4 (36.4%) 31 (50.8%) 46 (64.8%) 6 (14.3%)
  5-FU + Oxaliplatin 
+ RT 7 (63.6%) 30 (49.2%) 25 (35.2%) 0 (0.0%)
 RT mono 0 (0.0%) 0 (0.0%) 0 (0.0%) 36 (85.7%)
Surgery 0.26
 APE 1 (9.1%) 21 (34.4%) 13 (18.3%) 17 (40.5%)
 LAR 10 (90.9%) 40 (65.6%) 58 (81.7%) 25 (59.5%)
(Continued)
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 5-FU mono 3 (27.3%) 28 (45.9%) 34 (50.7%) 6 (14.3%)
 5-FU + Oxaliplatin 7 (63.6%) 30 (49.2%) 23 (34.3%) 0 (0.0%)
 none 1 (9.1%) 3 (4.9%) 10 (14.9%) 36 (85.7%)
 NA 0 0 4 0
Cause of non- 
cancer-specific death 1.0
 2nd malignancy 1 (100.0%) 1 (14.3%) 0 (0.0%) 0 (0.0%)
 heart failure 0 (0.0%) 4 (57.1%) 1 (50.0%) 5 (100.0%)
 Pneumonia 0 (0.0%) 1 (14.3%) 0 (0.0%) 0 (0.0%)
 pulmonary embolism 0 (0.0%) 1 (14.3%) 0 (0.0%) 0 (0.0%)
 surgical complication 0 (0.0%) 0 (0.0%) 1 (50.0%) 0 (0.0%)
ypT 1.0
 0 4 (36.4%) 7 (11.5%) 15 (21.1%) 5 (12.5%)
 1 0 (0.0%) 8 (13.1%) 8 (11.3%) 2 (5.0%)
 2 2 (18.2%) 13 (21.3%) 15 (21.1%) 19 (47.5%)
 3 3 (27.3%) 31 (50.8%) 29 (40.8%) 14 (35.0%)
 4 2 (18.2%) 2 (3.3%) 4 (5.6%) 0 (0.0%)
 NA 0 0 0 2
ypN 1.0
 negative 9 (81.8%) 35 (57.4%) 49 (69.0%) 28 (70.0%)
 positive 2 (18.2%) 26 (42.6%) 22 (31.0%) 12 (30.0%)
 NA 0 0 0 2
yM 1.0
 0 11 (100.0%) 48 (78.7%) 55 (77.5%) 28 (66.7%)
 1 0 (0.0%) 13 (21.3%) 16 (22.5%) 14 (33.3%)
DFS probability 0.29
 36-month estimate 1 0.81 0.68 0.72
 60-month estimate 0.78 0.64
CSS probability 1.0
 36-month estimate 0.91 0.92 0.86
 60-month estimate 0.87 0.74
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Böblingen) covering 27800 CpG islands represented by 
199,399 probe sequences with a length of 45–60 bp per 
probe sequence.
Quantitative DNA methylation (MassARRAY®)
Quantitative DNA methylation was assessed based 
on matrix-assisted laser desorption/ionization (MALDI) 
time-of-flight (TOF) mass spectrometry (MS) technique 
by Sequenom (referred to as MassARRAY® in the 
manuscript) as described previously [52]. Regions of 
interest as identified by MCIp analyses were targeted with 
PCR. Primers were derived from Sequenom´s (Hamburg, 
Germany) EpiDesigner platform or the EpiPanel 
(Supplementary Table 1). Relation of methylation specific 
PCR (MSP) CIMP primers to MassARRAY® primers is 
shown in Supplementary Figure 2. After sodium bisulfite 
modification of genomic DNA (Zymoresearch, Freiburg, 
Germany), the target gene regions were amplified by PCR. 
Subsequently deoxynucleotides in the PCR reaction were 
inactivated by dephosphorylation using shrimp alkaline 
phosphatase. By tagging the reverse PCR primer with the 
T7 recognition sequence, a single-stranded RNA copy 
of the template was generated by in vitro transcription. 
After base specific (U-specific) cleavage by RNase A, the 
cleavage products were analyzed using MassARRAY®. 
Signals with a 16 Da shift are representative for 
methylation events, and signal intensity is correlated with 
the degree of DNA methylation.
ChIP-seq data
Processed bigwig files for  chromatin-immunopre-
cipitation sequencing (ChIP-seq) data for EZH2 from 
the ENCODE consortium [56] were downloaded from 
the UCSC Genome Browser website for H1 human 
embryonic stem cells (GSM1003524), human umbilical 
vein endothelial cells (HUVEC, GSM1003518) and 
normal human astrocytes (GSM1003532). Signal files 
were overlayed and viewed in the Integrated Genome 
Viewer (version 2.3).
Statistics
CpG island array data were processed and normalized 
according to previous analyzes [53]. In short background 
was corrected and log2-ratio transformation was performed 
using the NormExp method with offset = 50 [54]. Intensity-
based LOESS normalization on rank-invariant probes and 
negative controls was used to reduce variation between 
co-hybridized samples [55]. For normalization between 
arrays, log-intensity averages (A-values) and log-intensity 
ratios (M-values) were scaled to have the same median-
absolute-value across the arrays. DMRs were defined 
using the following stepwise criteria: (i) a “region” in the 
genome which may become a DMR is a coherent stretch 
with more than one array probe and in which two vicinal 
probes are separated by ≤500 bp; (ii) per tumor sample 
(array), only the top 5% (i.e. 10,000) hypermethylated 
probes are considered; (iii) a DMR is represented by at 
least two vicinal top 5%-probes allowing a gap of a single 
non-top-5% probe; (iv) DMRs were chosen for further 
analysis if they were present in all, or at least in all except 
one representative arrays. Finally, the top five DMRs for 
either ypN positivity or negativity, and complete or non-
responder were chosen, respectively. The methylation 
levels of CpGs in the test set were filtered according to 
their correlation with disease-free survival (DFS) by a 
Cox regression with the methylation level as explanatory 
variable. DFS was measured starting from surgery; local 
recurrence or metastases were counted as an event and non-
cancer related death was censored. In this patient cohort, no 
isolated local recurrence (without the appearance of distant 
metastases) was diagnosed. The methylation sites with a 
resulting p-value of less then 5% were clustered. Samples 
with missing methylation information for more than 60% 
of the methylation were excluded from further analysis. 
The patients were then grouped according to the main 
branches resulting from this clustering and the Kaplan-
Meier estimates of these groups were compared using 
a log-rank test. Two Cox models were fitted using age, 
gender, uN, and the clustering as explanatory variables: a 
full model and a model without the methylation clustering. 
The explanatory variables were chosen to include the 
(potentially) relevant parameters known at treatment onset 
and which demonstrate sufficient variation in the studied 
patient cohort. Both models were compared by means of 
an analysis of deviance, and a p value assessing the change 
in log-likelihood was calculated. The patients from the 
validation set were assigned to one of the clusters based on 
their methylation pattern by means of the nearest centroid 
distance, and the Kaplan-Meier curves of the resulting 
patient groups were again compared using a log-rank test. 
The measured methylation sites from the validation set were 
also correlated to DFS using a CpG-wise Cox regression 
and the overlap of the methylation sites with a resulting 
p-value of less than 5% to the identified DFS-related CpGs 
from the test set was determined. An analogous correlation 
analysis for DFS was also performed per DNA region with 
the averaged methylation level of the CpGs connected 
to each DNA region. All analyses were performed using 
R (version 2.15). To compare data sets from the CIMP panel 
and the whole genome approach, their ability (alone and 
combined) to classify into good or bad prognosis groups 
were compared. Subsequently, the classification results 
were implemented in a multivariate Cox model and tested 
in an analysis of variance.
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